Tegoprazan
- Generic Name
- Tegoprazan
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19F2N3O3
- CAS Number
- 942195-55-3
- Unique Ingredient Identifier
- W017G7IF4S
- Background
Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases. This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels. It has also been observed to be efficacious independent of food intake.
- Indication
用于治疗胃食管反流病、糜烂性食管炎及消化性溃疡等酸相关疾病。
Tegoprazan-Based Dual Therapy With Amoxicillin vs Tetracycline for H. Pylori Eradication
- Conditions
- Helicobacter Pylori EradicationHigh-dose Dual Therapy
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Target Recruit Count
- 87
- Registration Number
- NCT06977841
- Locations
- 🇨🇳
Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China
Tegoprazan and Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment
- Conditions
- Peptic Ulcer Bleeding
- Interventions
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Mario Steffanus
- Target Recruit Count
- 162
- Registration Number
- NCT06894992
- Locations
- 🇮🇩
Cipto Mangunkusumo National General Hospital, Jakarta, DKI Jakarta, Indonesia
🇮🇩Atma Jaya Hospital, Jakarta, DKI Jakarta, Indonesia
Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia
- Conditions
- Ordinary Disorder Needed Planned Surgery and General Anesthesia
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Kim, Young Sung
- Target Recruit Count
- 174
- Registration Number
- NCT06743243
- Locations
- 🇰🇷
Korea University Medical Center, Guro Hospital, Seoul, Korea, Republic of
A Phase I Study of LX22001 for Injection in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Target Recruit Count
- 70
- Registration Number
- NCT06561542
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
- Conditions
- Helicobacter Pylori Infection Chronic Gastrit
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 208
- Registration Number
- NCT06523764
PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT06332638
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Hospital General de México Dr. Eduardo Liceaga
- Target Recruit Count
- 160
- Registration Number
- NCT06318104
Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT06164834
- Locations
- 🇰🇷
Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of
Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 381
- Registration Number
- NCT05933031
- Locations
- 🇰🇷
Chung-Ang University Hosptial, Seoul, Korea, Republic of
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-06-23
- Target Recruit Count
- 22
- Registration Number
- NCT05915871
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.